Study on Daraxonrasib and Daraxonrasib with Chemotherapy as First Treatment for Metastatic Pancreatic Cancer
Sponsor: Revolution Medicines, Inc.
ClinicalTrials ID:NCT07491445
This clinical trial is testing a new drug, Daraxonrasib, alone or with chemotherapy, to see if it works better than standard chemotherapy for treating metastatic pancreatic cancer.
Patient Parameters
| Parameter | Options |
|---|
Program Overview
The study aims to find out if the new drug Daraxonrasib, either by itself or combined with chemotherapy drugs gemcitabine and nab-paclitaxel, can help patients with metastatic pancreatic cancer live longer or delay the progression of their disease compared to the usual chemotherapy treatment.
Description
This is a global study where participants will be randomly assigned to one of three groups: one group will receive Daraxonrasib alone, another group will receive Daraxonrasib with the chemotherapy drugs gemcitabine and nab-paclitaxel, and the third group will receive the standard chemotherapy treatment of gemcitabine and nab-paclitaxel. The goal is to see which treatment is more effective in improving the time patients live without their cancer getting worse and their overall survival.
Eligibility Criteria
Inclusion Criteria
- Must be at least 18 years old and agree to participate.
- Have a good general health status, able to carry out daily activities with minimal restrictions.
- Have a confirmed diagnosis of pancreatic cancer that has spread to other parts of the body.
- Diagnosed with metastatic cancer within the last 6 weeks.
- Have a known RAS gene mutation status.
- Have cancer that can be measured by scans.
- Have good organ function, including bone marrow, liver, and kidneys.
- Able to swallow pills.
Exclusion Criteria
- Have received previous cancer treatment for metastatic cancer or any treatment targeting the RAS gene.
- Have untreated cancer that has spread to the brain or spinal cord.
- Have any medical conditions that affect the ability to take or absorb the study medication.
- Have had major surgery within the last 28 days.
- Are unable or unwilling to attend study visits or follow study procedures.
Locations
| FACILITY | ZIP | CITY | STATE |
|---|---|---|---|
| Dana-Farber Cancer Institute | 02215 | Boston | Massachusetts |
| Comprehensive Cancer Centers of Nevada | 89052 | Henderson | Nevada |
| Taylor Cancer Research Center | 43537 | Maumee | Ohio |
Get This Program In Your Inbox
Receive detailed information about this treatment opportunity to review with your healthcare provider.